Neue Behandlungsmöglichkeiten der Endometriose mit GnRH-Antagonisten

W. Küpker, R. Felberbaum
In: Der Gynäkologe · 2020 · vol. 53(8) , pp. 522–528 · doi:10.1007/s00129-020-04633-z · W3041539532
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-10 ⓘ

Peptide GnRH antagonists maintain estradiol secretion for symptom relief without side effects in endometriosis patients, and new oral nonpeptidic GnRH antagonists are effective for dysmenorrhea and endometriosis pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

The paper reviews how GnRH agonists have long been used in endometriosis and uterine fibroids, but their current role is limited because potent progestins have replaced them and steroid-withdrawal side effects make long-term use questionable. It contrasts peptide GnRH antagonists, which can maintain basal estradiol secretion via an intermediate depot and allow titration of estradiol into a therapeutic window to achieve symptom freedom without reported mood swings, hot flashes, or libido loss, while noting that peptide/strategic approaches have limitations and that long-term outcomes are still awaited. The authors also describe the development of nonpeptidic, orally active GnRH antagonists and report effectiveness for dysmenorrhea and chronic endometriosis-associated pain, with further long-term safety experience pending. Relevance to endometriosis: the paper is centrally about endometriosis treatment with GnRH antagonists, including the rationale and clinical efficacy context for peptide and oral nonpeptide GnRH antagonists in endometriosis-associated pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK